# EDGAR Filing Document

**Accession Number:** 0001840229
**File Stem:** 0001171843-25-005405
**Filing Date:** 2025-8
**Character Count:** 12374
**Document Hash:** 2ee63646d579b93a067a701a733062ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-005405.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001171843-25-005405

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MiNK Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40908
- **FILM NUMBER:** 251214365

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 212-994-8250

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AgenTus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210112

?xml version='1.0' encoding='ASCII'? Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): August 14, 2025
_______________________________

#### MiNK Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40908** | **82-2142067** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

#### 149 Fifth Avenue, Suite 500

#### New York, New York 10010
(Address of Principal Executive Offices) (Zip Code)

(212) 994-8250

(Registrant's telephone number, including area code)

#### Not applicable
(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.00001 par value per share | INKT | The NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On August 14, 2025, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibit

The following exhibit is furnished herewith:

[99.1](exh_991.htm) [Press Release dated August 14, 2025](exh_991.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MiNK Therapeutics, Inc.** | **MiNK Therapeutics, Inc.** |
| Date: August 14, 2025 | By: | <u>/s/ Christine M. Klaskin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Christine M. Klaskin |
|  |  | Principal Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results**

* Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer

* Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing

* **New clinical grant awarded** to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.

"In Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding," said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. "Since quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD — we can achieve substantial clinical program advancements."

**<u>Highlights from Q2 2025</u>**

* **Durable Complete Remission in Metastatic Testicular Cancer**: *Nature's Oncogene* publication of a landmark case of a patient with treatment-refractory metastatic testicular cancer who achieved a durable complete remission following a single infusion of agenT-797 (allo-INKTs) in combination with checkpoint blockade. The patient remains disease-free more than two years post-treatment.

* **Strengthened Balance Sheet**: Increased cash reserves extending runway beyond mid-2026 to advance clinical programs.

* **Department of Defense STTR Grant Awarded for GvHD:** Competitive DOD STTR grant awarded to advance development of iNKTs for graft-versus-host disease (GvHD) prevention and treatment; program launched.

* **NEW Clinical Grant Awarded for GvHD**: Additional clinical competitive grant awarded to initiate a first-in-human clinical trial of iNKTs in GvHD, with trial initiation targeted in 2H2025.

* **Progress in Phase 2 Gastric Cancer Study**: Phase 2 trial of agenT-797 in second-line gastric cancer anticipated additional clinical readouts in 2025.

* **Peer-Reviewed Review of iNKT Cell Therapy**: A *Frontiers in Immunology* featured MiNK's platform, highlighting iNKT cells' can remodel the tumor microenvironment and overcome therapeutic resistance, showcasing CAR-iNKTs, such as MiNK-215 as a next-generation solution for solid tumors.

**Financial Highlights**

* **Cash Position:** MiNK ended Q2 2025 with approximately $1.6 million in cash and cash equivalents and subsequently raised $13 million through equity sales, providing expected runway into mid-2026. 

* **Net Loss:** Net loss for Q2 2025 was $4.2 million, or $1.06 per share, compared to $2.7 million, or $0.73 per share for Q2 2024. For the first half of 2025, net loss was $7 million, or $1.76 per share compared to $6.5 million or $1.82 per share for the first half of 2024. Current period results reflect ongoing activity supporting our agent-797 programs and non-cash expenses including the impact of repricing of certain equity awards.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Summary Consolidated Financial Information** | **Summary Consolidated Financial Information** | **Summary Consolidated Financial Information** | **Summary Consolidated Financial Information** | **Summary Consolidated Financial Information** |
| **Condensed Consolidated Balance Sheet Data** | **Condensed Consolidated Balance Sheet Data** | **Condensed Consolidated Balance Sheet Data** | **Condensed Consolidated Balance Sheet Data** | **Condensed Consolidated Balance Sheet Data** |
| (in thousands) | (in thousands) | (in thousands) | (in thousands) | (in thousands) |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
|  | June 30, 2025 |  |  |  |
| Cash and cash equivalents | $1682 |  |  |  |
| Cash raised since quarter end | 13012 |  |  |  |
| **Other Financial Information** | **Other Financial Information** | **Other Financial Information** | **Other Financial Information** | **Other Financial Information** |
| (in thousands) | (in thousands) | (in thousands) | (in thousands) | (in thousands) |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | (unaudited) |
|  | Three months ended June 30, | Three months ended June 30, | Six months ended June 30, | Six months ended June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| Cash used in operations | $1569 | $2291 | $2910 | $4833 |
| Non-cash expenses | 1501 | 491 | 2336 | 1141 |
| Net loss | 4237 | 2702 | 7004 | 6515 |
| Net loss per share | 1.06 | 0.73 | 1.76 | 1.82 |

---

**Conference Call and Webcast Information**

MiNK will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET.

To access the live call, please dial **(800) 715-9871 (U.S.) or (646) 307-1963** (International) and reference conference ID 1149380.

A live webcast and replay will be available in the Events & Presentations section of MiNK's investor website at https://investor.minktherapeutics.com/events-and-presentations.

**About MiNK Therapeutics**

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit <u>https://minktherapeutics.com</u> or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

**Forward Looking Statements**

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

**Investor Contact**

917-362-1370 \| <u>investor@minktherapeutics.com</u>

**Media Contact**

781-674-4422 \| <u>communications@minktherapeutics.com</u>